Neurocrine Ends Work With Voyager on Gene Therapy on Extended Trial Hold
Neurocrine Biosciences announced that it is stopping its work with Voyager Therapeutics to further develop VY-AADC (NBIb-1817) as a potential one-time gene therapy for Parkinson’s disease. The therapy, by Voyager and being advanced with Neurocrine’s support, is in a Phase 2 clinical trial (…